This is the seventeenth conference focusing on issues related to Epilepsy Therapies & Diagnostic Developments (ETDD) from preclinical discoveries through clinical evaluations. We are fortunate to have a robust epilepsy drug and device pipeline, fueled by excellent science and novel ideas. We are entering an exciting era where therapies targeted at disease modification , rather than just anti-seizure treatment are emerging, and there is a focus on personalized treatments. There are also many treatments in the pipeline for orphan diseases. There is a burgeoning pipeline of wearable and implantable diagnostic devices. New therapeutic devices are also under development. New innovations in therapy and diagnostics may face roadblocks such as complex regulatory requirements, increased payer expectations, and issues in data quality, but progress has been made. At each ETDD conference, we re-evaluate strategies to ensure continued advancement. There is always the opportunity to learn from the past as we move into the future. This symposium will bring together representatives from academia, industry, and the NIH, to review what has been learned and to discuss strategies to enhance epilepsy therapy and diagnostics development.